Adis Journals
OlopatadineMometasone.PNG (129.74 kB)

Olopatadine/mometasone combination nasal spray in allergic rhinitis: a profile of its use

Download (129.74 kB)
online resource
posted on 2020-09-28, 02:48 authored by Yvette Lamb


Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Y. N. Lamb is an employee of Adis International Ltd./Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Q&A can be found here


Olopatadine/mometasone furoate combination nasal spray (Ryaltris®; referred to hereafter as olopatadine/mometasone), a convenient fixed-dose combination (FDC) of the antihistamine olopatadine and the corticosteroid mometasone furoate, is approved in Australia for the treatment of symptoms associated with allergic rhinitis (AR) and rhinoconjunctivitis in patients 12 years of age and older. Olopatadine/mometasone is an effective treatment for seasonal and perennial AR, providing statistically significant and clinically meaningful relief of nasal symptoms relative to monocomponents and/or placebo in clinical trials. Ocular symptoms of AR were also improved with olopatadine/mometasone. Benefits of olopatadine/mometasone were maintained over 52 weeks of treatment in adults and adolescents with perennial AR. Olopatadine/mometasone is generally well tolerated, with most treatment-emergent adverse events being of mild to moderate severity.

© Springer Nature Switzerland AG 2020


Usage metrics

    Drugs & Therapy Perspectives



    Ref. manager